e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice
Akihiro Takemasa, Yoshiki Ishii, Takeshi Fukuda
Source:
Eur Respir J 2012; 40: 1475-1482
Journal Issue:
December
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Akihiro Takemasa, Yoshiki Ishii, Takeshi Fukuda. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2012; 40: 1475-1482
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Neutrophil elastase is necessary for increases in active TGF-β in bleomycin-induced pulmonary fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 199s
Year: 2001
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis
Source: Eur Respir J 2015; 46: 384-394
Year: 2015
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 461s
Year: 2005
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Source: Eur Respir J 2007; 29: 240-250
Year: 2007
Neutrophilic inflammation predisposes to structural lung disease in cystic fibrosis (CF) via neutrophil elastase activity
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009
The role of matrix metalloproteinases in cystic fibrosis lung disease
Source: Eur Respir J 2011; 38: 721-727
Year: 2011
Decreased levels of secretory leucoprotease inhibitor in the
pseudomonas
-infected cystic fibrosis lung are due to neutrophil elastase degradation
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009
Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy
Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Year: 2008
Neutrophil elastase and lung damage in cystic fibrosis
Source: International Congress 2018 – Proteases: at the cutting edge of lung disease
Year: 2018
The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice
in vivo
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Inhibition of airway proteases in cystic fibrosis lung disease
Source: Eur Respir J 2008; 32: 783-795
Year: 2008
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2002; 20: Suppl. 38, 487s
Year: 2002
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis.
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 501s
Year: 2001
Neutrophil elastase inhibitor sivelestat ameliorates gefitinib, naphthalene-induced acute pneumonitis in mice
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
Neutrophil extracellular traps contribute to pulmonary fibrosis induced by bleomycin
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
Inhibition of pulmonary collagen-I, III and fibrotic cytokins in bleomycin induced pulmonary fibrosis by okam J201
Source: Eur Respir J 2005; 26: Suppl. 49, 81s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept